US Patent

US11103494 — Methylphenidate extended release chewable tablet

Formulation · Assigned to Tris Pharma Inc · Expires 2033-08-14 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an extended release chewable tablet formulation of methylphenidate hydrochloride that can be scored and retains its extended release profile.

USPTO Abstract

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

Drugs covered by this patent

Patent Metadata

Patent number
US11103494
Jurisdiction
US
Classification
Formulation
Expires
2033-08-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Tris Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.